Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate The Impact on Skin Quality Attributes by Juvederm® Volite Injection on Healthy Volunteers

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy participants~* Participants with Fitzpatrick skin type II or III~* Participant willing to receive Juvéderm® VOLITE in the forearms and agrees to complete all study required procedures, including having 6 cutaneous punch biopsies taken in the forearms and blood drawn (Human immunodeficiency virus \[HIV\], B and C hepatitis analysis at screening)~* Written informed consent and data privacy consent obtained~Exclusion Criteria:~* Pregnant or nursing woman or planning a pregnancy during the study~* Participant participating to another research on human beings or being in an exclusion period for a previous study~* Intensive exposure to sunlight or ultraviolet (UV)-rays within the previous month and foreseen during the study~* Participant having other resorbable filling product injections, a laser treatment, an ultrasound-based treatment, radiation treatment, a dermabrasion, a surgery, a deep chemical peeling or other ablative procedure on the studied zones within the past 12 months prior to study start~* Participant with subcutaneous retaining structure on the studied zones (meshing, threads, gold strand)~* Participant having received injections of permanent or semi-permanent filling products in the studied zones~* Participant under anti-coagulant treatment or treatment liable to interfere with the healing process or hemostasis, during the previous month and during the study~* Participant receiving or is planning to receive anti-inflammatory drugs (oral/injectable corticosteroids or Nonsteroidal anti-inflammatory drugs (NSAIDs), e.g., aspirin, ibuprofen), or other substances known to increase coagulation time (herbal supplements with garlic or ginkgo biloba, etc) for 10 days prior to study treatment and 3 days after~* Participant under immunosuppressive therapy

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Juvéderm® VOLITE (Type: EXPERIMENTAL): Participants received Juvéderm® VOLITE, intradermal injection on a zone of 8 centimeter (cm) x 4 cm (32 cm\^2) of the volar left forearm on Day 0. The dose to be injected was decided by the investigator as per the Directions for Use. A maximum of 1 milliliter (mL) was injected on the zone treated.

Based on this trial design, predict the completion outcome and termination type (if applicable).